Viral vector-based therapeutic cancer vaccines

C Larocca, J Schlom - The Cancer Journal, 2011 - journals.lww.com
Most viruses are naturally immunogenic and can be engineered to express tumor antigen
transgenes. Moreover, many types of recombinant viruses have been shown to infect …

[HTML][HTML] Insight to drug delivery aspects for colorectal cancer

A Gulbake, A Jain, A Jain, A Jain… - World journal of …, 2016 - ncbi.nlm.nih.gov
Colorectal cancer (CRC) is the third most common cancer diagnosed worldwide in human
beings. Surgery, chemotherapy, radiotherapy and targeted therapies are the conventional …

Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy

M Chakraborty, SI Abrams, K Camphausen… - The Journal of …, 2003 - journals.aai.org
CD8+ CTL play important roles against malignancy in both active and passive
immunotherapy. Nonetheless, the success of antitumor CTL responses may be improved by …

Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients

K Odunsi, J Matsuzaki, J Karbach… - Proceedings of the …, 2012 - National Acad Sciences
Recombinant poxviruses (vaccinia and fowlpox) expressing tumor-associated antigens are
currently being evaluated in clinical trials as cancer vaccines to induce tumor-specific …

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer

RA Madan, PM Arlen, M Mohebtash… - Expert opinion on …, 2009 - Taylor & Francis
Prostvac is a prostate cancer vaccine regimen consisting of a recombinant vaccinia vector
as a primary vaccination, followed by multiple booster vaccinations employing a …

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.

PM Arlen, JL Gulley, C Parker, L Skarupa… - Clinical cancer research …, 2006 - AACR
PURPOSE: Docetaxel has activity against androgen-independent prostate cancer and
preclinical studies have shown that taxane-based chemotherapy can enhance antitumor …

A triad of costimulatory molecules synergize to amplify T-cell activation

JW Hodge, H Sabzevari, A Gómez Yafal, L Gritz… - Cancer research, 1999 - AACR
The activation of a T cell has been shown to require two signals via molecules present on
professional antigen-presenting cells: signal 1, via a peptide/MHC complex; and signal 2 …

Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement

CT Garnett, J Schlom, JW Hodge - Clinical Cancer Research, 2008 - AACR
Purpose: Taxanes comprise some of the most widely used cancer chemotherapeutic agents.
Members of this drug family, including docetaxel, are commonly used to treat breast …

HER-2/neu Is a Tumor Rejection Target in Tolerized HER-2/neu Transgenic Mice

RT Reilly, MBC Gottlieb, AM Ercolini, JPH Machiels… - Cancer research, 2000 - AACR
Abstract HER-2/neu (neu-N) transgenic mice, which express the nontransforming rat proto-
oncogene, develop spontaneous focal mammary adenocarcinomas beginning at 5–6 …

Strategies for cancer vaccine development

M Vergati, C Intrivici, NY Huen… - BioMed research …, 2010 - Wiley Online Library
Treating cancer with vaccines has been a challenging field of investigation since the 1950s.
Over the years, the lack of effective active immunotherapies has led to the development of …